Melanotan II dosage in clinical trials
What dose levels researchers actually tested, quoted from the trial registry and the published reports — so the numbers circulating online can be checked against their source.
Doses in published trials
| Trial | Population | Dose arms | Schedule | Ref. |
|---|---|---|---|---|
| Phase I pilot | 3 healthy men | 0.01 mg/kg, escalated to 0.025–0.03 mg/kg | SC, weekdays for 2 weeks, alternating with saline | 1 |
| Crossover, psychogenic ED | 10 men | 0.025 mg/kg | SC, versus vehicle placebo | 2 |
| Crossover, organic ED | 10 men | 0.025 mg/kg | SC, twice each for drug and vehicle | 3 |
ClinicalTrials.gov lists 1 Melanotan II studies, but none of their registered arms names Melanotan II together with a dose, so this page quotes the published reports only.
References
Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.
- 1 PubMed Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 1996. PMID 8637402; doi:10.1016/0024-3205(96)00160-9.
- 2 PubMed Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998. PMID 9679884.
- 3 PubMed Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000. PMID 11018622; doi:10.1016/s0090-4295(00)00680-4.